Home Newsfeeds Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $208

Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $208

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $210 to $208.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $210 to $208.

What’s Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

By Vandana Singh

February 20, 1:30 PM

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

CMMB

News

Amdocs Collaborates With Virgin Media O2 To Enhance Access To Streaming Services

By Benzinga Newsdesk

May 8, 5:32 PM

Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced that Virgin Media O2, one of the United Kingdom's leading communications service providers, is

DOX

ISS Joins Glass Lewis In Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees At 2023 Annual General Meeting

By Benzinga Newsdesk

May 2, 4:54 PM

Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditorsCompany reminds shareholders to vote today to

AUPH